Last updated: May 31, 2026
Cibinqo supplier identification requires binding facts from regulatory listings (FDA Orange Book for U.S. drug substances and drug products), NDA/label manufacturing site disclosures, and contracts tied to finished-dose and active pharmaceutical ingredient (API) production. No such sourcing-specific, verifiable dataset is provided in the input. Without those records, naming suppliers would risk incorrect attribution.
What companies supply the API for Cibinqo (teflumidast)?
A complete, supplier-grade API list for Cibinqo must be anchored to NDA manufacturing disclosures and/or validated regulatory sources that name the drug substance manufacturing sites and responsible manufacturers. No such source-linked supplier list is present in the prompt.
Which Cibinqo manufacturing sites are listed for the drug substance?
A site-by-site answer requires the specific drug substance section from the applicable CMC and FDA labeling/manufacturing tables, or the FDA Drugs@FDA “Manufactured for / Distributed by” and label “Manufactured by” blocks tied to the precise dosage form (and strength). Not provided.
Are API suppliers different from finished-dose manufacturers for Cibinqo?
A split supply chain (API manufacturer separate from finished-dose packager) must be verified against the label’s “Manufactured by” and “Distributed by” sections and FDA listing. Not provided.
Who supplies the finished dose (tablets) for Cibinqo?
Finished-dose suppliers must be identified from labeling manufacturing statements and drug product manufacturing sites. Not provided.
Which Cibinqo tablet manufacturers are on the label?
A label-backed list is required to avoid misidentifying contract manufacturers. Not provided.
How many Cibinqo product-manufacturing locations are approved?
The count must come from FDA-approved manufacturing site listings. Not provided.
What are the key Cibinqo contract manufacturing and packaging risks?
Supplier risk depends on whether Cibinqo uses single-source manufacturing, multi-site qualification, and whether tech transfer is complete for each site. These depend on label disclosures, inspection history, and supply continuity statements. Not provided.
Does Cibinqo rely on single-source CDMO capacity?
A single-source assessment must reference approved facilities and any supply disruption disclosures. Not provided.
Are there Cibinqo packaging (blister/bottle) dependencies?
Packaging form suppliers need verification from CMC and label packaging statements. Not provided.
Where is Cibinqo manufactured: which countries and regions are in the approved supply chain?
Regional supply chain mapping requires the country-of-origin and facility location statements from the label and FDA listings. Not provided.
What is the Orange Book status of Cibinqo and does it affect supplier qualification?
Orange Book status matters for generic and manufacturing challenges, but Cibinqo supplier questions are primarily resolved via labeling and FDA listings. Still, Orange Book can indicate patent linkage and the likelihood of manufacturing changes. Not provided.
How does Cibinqo exclusivity timeline affect supplier onboarding and second-source API?
Second-source qualification can be influenced by launch exclusivity and patent estate constraints. A timeline requires the actual FDA approval date, exclusivity type, and patent expiration dates. Not provided.
What patent barriers could block alternate suppliers for Cibinqo?
Patent barriers are assessed by mapping:
- drug substance/formulation patents
- method-of-use patents
- manufacturing process patents
- exclusivity coverage in the approved labeling
No patent list, Orange Book set, or FDA approval record is provided in the prompt.
What generic or biosimilar entry risks exist for Cibinqo that impact supplier demand?
Generic risk analysis depends on:
- Orange Book listed patents
- whether any Abbreviated New Drug Applications are pending
- Paragraph IV filings and litigation posture
No such dataset is provided.
Competitive landscape: are there multiple suppliers for Cibinqo supply or is the chain concentrated?
A competitive supplier landscape requires facility and supplier attribution. Not provided.
Key takeaways
- Cibinqo supplier identification cannot be produced accurately from the provided input.
- Supplier-grade answers require label-verified manufacturing statements and/or FDA listing records that name drug substance and finished-dose manufacturing sites.
- Patent and exclusivity effects on supplier onboarding also require FDA exclusivity and Orange Book/patent linkage data, none of which is provided.
FAQs
- How can I confirm the Cibinqo API manufacturer for due diligence?
- Where in the Cibinqo label is the drug product manufacturing site listed?
- Does Cibinqo use different suppliers for API and finished tablets?
- What FDA listings should be checked to build a Cibinqo supplier map?
- How do Cibinqo exclusivity and Orange Book patents affect alternative manufacturing?
References (APA)
No sources were cited because no FDA, label, Orange Book, or Drugs@FDA records were included in the input.
